Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat and sterile alpha motif containing 1 (LRSAM1) is a cytoplasmic E3 ubiquitin-protein ligase highly expressed in spinal cord motoneurons and developing muscle tissue[5][7]. It features leucine-rich repeats, a RING-type zinc finger, and a sterile alpha motif (SAM) domain[5]. LRSAM1 mediates monoubiquitination of TSG101, thereby regulating endocytic and exocytic cargo sorting and participating in protein degradation pathways[7][9]. It is involved in immune defense, clearing intracellular bacteria through the autophagy pathway, and has been implicated in cancer cell growth and neuron health[7][5]. Mutations in LRSAM1 are causative for the inherited axonal neuropathy Charcot-Marie-Tooth disease type 2P[1][7][9]. Its precise role as a therapeutic target is under investigation, and there are currently no directly approved drugs targeting LRSAM1.
Targeted by hypothetical modulators of E3 ubiquitin ligase activity (therapeutics may inhibit or enhance ubiquitination-mediated processes); specific approved interacting drugs not established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat and sterile alpha motif containing 1 (LRSAM1).